TY  - JOUR
SP  - 1
N2  - Background: Inhibition of the oncogenic fusion-gene EML4-ALK is a current first-line approach for patients with stage IV non-small cell lung cancer. While FISH was established as the gold standard for identifying these patients, there is accumulating evidence that other methods of detection, i.e., immunohistochemistry and next-generation sequencing (NGS), exist that may be equally successful. However, the concordance of these methods is under investigation.   Case presentation: Adding to the current literature, we here report a 56 year old female never-smoker with stage IV lung adenocarcinoma whose biopsy was IHC and FISH inconclusive but positive in NGS. Retroactive profiling of the resection specimen corroborated fusion reads obtained by NGS, FISH-positivity and showed weak ALK-positivity by IHC. Consequently, we diagnosed the case as ALK-positive rendering the patient eligible to crizotinib treatment.   Conclusions: With IHC on biopsy material only, this case would have been overlooked withholding effective therapy.
AV  - public
SN  - 1746-1596
TI  - Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report
Y1  - 2016///
JF  - Diagnostic Pathology
ID  - heidok22203
VL  - 11
CY  - London
IS  - 133
UR  - https://archiv.ub.uni-heidelberg.de/volltextserver/22203/
A1  - Volckmar, Anna-Lena
A1  - Endris, Volker
A1  - Bozorgmehr, Farastuk
A1  - Lier, Clemens
A1  - Porcel, Carlota
A1  - Kirchner, Martina
A1  - Leichsenring, Jonas
A1  - Penzel, Roland
A1  - Thomas, Michael
A1  - Schirmacher, Peter
A1  - Warth, Arne
A1  - Stenzinger, Albrecht
EP  - 6
PB  - BioMed Central
ER  -